About Us
Our Mission
Advancing regenerative medicine through programmable resorbable biomaterials that improve patient outcomes and empower surgeons to innovate.
Our Story
Founded in 2018, SDIP Innovations was established by biomaterials scientists and engineers with a vision to translate advanced materials science into practical medical technologies.
From our origins in research and development, we have grown into an established regenerative medicine company focused on developing scalable biomaterial platforms for unmet clinical needs.
Today, SDIP Innovations operates across Australia, with subsidiary offices in Hong Kong and New Zealand, supporting the development and advancement of next-generation regenerative solutions for global healthcare markets.
Advanced In-House Manufacturing
SDIP Innovations operates an advanced manufacturing facility in Sydney, Australia, where research, development, and production are integrated under one roof.
Our in-house manufacturing capability provides complete control over the production process, enabling consistent quality, efficient scale-up, and rapid translation of innovation into commercial products.
Meet our Leadership Team
Dr Maryam Parviz
Chief Executive Officer and Co-founder
Dr Maryam Parviz is the co-founder and CEO at “SDIP Innovations” with more than 12 years’ experience in the Biomaterial field.
Read more
Dr Maryam Parviz is a biomedical engineer, medtech entrepreneur and commercialisation leader with experience translating scientific innovation into clinically and commercially viable medical devices. She holds a PhD from UNSW Australia and BSc and MSc degrees in Biomedical Engineering from Tehran Polytechnic.
As Co-founder and CEO of SDIP Innovations, Maryam has led the company’s growth since 2018 – from technology development and building an expert team to fundraising, quality and manufacturing systems, FDA clearance and international market entry for the JAZBI™ biomaterial platform. Before founding SDIP, she trained in medical-device commercialisation and worked with startups on translating research into clinical products.
Maryam has guest lectured in the Commercialisation of Science at the University of Melbourne for several years. She has also served as a mentor or selection-panel member for programs including UCSF Rosenman Innovators (San Francisco), Plug and Play MedTech (Warsaw, Indiana), UNSW Founders, Impact X (Sydney, Australia) and the Australian Society for Medical Entrepreneurship & Innovation supporting the next generation of health and technology founders.
Dr Iman Manavitehrani
Chief Scientific Officer and Co-founder
Dr Iman Manavitehrani is the co-founder and CSO at SDIP. He is an engineer, entrepreneur and the inventor of JAZBI™ technology.
Read more
Dr Iman Manavitehrani is a biomedical engineer, scientist and entrepreneur with more than 15 years of experience in biomaterials, tissue engineering and regenerative medicine, with a strong focus on translating scientific discoveries into commercially viable medical technologies.
After completing his PhD in Biomolecular Engineering at the University of Sydney and working as a biomaterials scientist at The Children’s Hospital at Westmead, Iman co-founded SDIP Innovations in 2018. He is the primary inventor of the core JAZBI™ technology and its expanding product portfolio, and is an inventor on 12 patents.
Iman spent three years in the San Francisco Bay Area immersed in its biotechnology and medical-device ecosystem before returning to Australia, where he led the establishment of SDIP’s ISO-certified medical-device manufacturing operations from the ground up. He has since led the company to expand JAZBI™ internationally, establishing SDIP operations in Hong Kong and New Zealand while continuing to lead the company’s research, product development and global commercialisation.
Fred Dinger
Chair of the Board
Fred Dinger has over 25 years of experience with both large and small medical device companies.
Read more
Prior to Aerin Medical, Fred served as President and Chief Executive Officer at ENTrigue Surgical, C2M Medical and OsteoBiologics Inc (OBI), and has held leadership positions with A-Med Systems, where he served as Vice President and Chief Operating Officer, as well as Linvatec Corporation and Xomed Surgical Products that all have been acquired by large corporations.
Fred earned a Bachelor of Science in Mechanical Engineering from Cornell University and a Master of Science in Engineering Management from the University of South Florida. Fred and another three ex-members of Osteobiologics join SDIP as they are so passionate about providing improved bone implants for patients around the globe.
Dr Brett Fritsch
Clinical Advisor Orthopaedic Surgeon
Dr Brett Fritsch is an orthopaedic surgeon in Sydney, Australia, specialising in knee surgery.
Read more
He is a teaching surgeon at Royal Prince Alfred Hospital (affiliated with the University of Sydney), and a member of the Australian Orthopaedic Association, The Australian Knee Society and the International Society of Arthroscopy, Knee Surgery and Orthopaedic Sports medicine (ISAKOS).
He is the director of the Sydney Orthopaedic Research Institute (SORI).
Prof. Mohammad Diab
Clinical Advisor Orthopaedic Surgeon
Dr. Mohammad Diab is an orthopaedic surgeon and chief of pediatric orthopaedics at UCSF Benioff Children’s Hospital.
Read more
He specializes in treating musculoskeletal conditions in children and teenagers, and residual childhood deformities in young adults. Diab earned his medical degree from Stanford University. He completed a residency in general orthopaedic surgery at the University of Washington and a fellowship in pediatric orthopaedic surgery at Harvard University.
He came to UCSF in 2002. Diab is a member of the American Academy of Orthopaedic Surgeons, American Academy of Pediatrics, American Medical Association, Pediatric Orthopaedic Society of North America and Scoliosis Research Society. He held an Academy of Medical Educators chair at UCSF for a decade and now holds the endowed chair in pediatric orthopaedic education.
Born in Cairo, Diab completed his early education in the United Kingdom. Rooted in his undergraduate major of classical studies and spurred by his interest in the history of medicine, he is the writer of Lexicon of Orthopaedic Etymology book.
Prof Ehsan Jabbarzadeh
Science Commercialisation Advisor
Dr Jabbarzadeh is a Venture Capital Partner at IAG Capital Partners, an early-stage investment firm specialising in life sciences and advanced computing startups.
Read more
He also holds a position of Full Professor of Chemical and Biological Engineering and Director of Engineering Entrepreneurship at the University of South Carolina. His professional career is represented by a Venn diagram of innovation, entrepreneurship, and academic leadership. As an innovator, directed a federally funded research laboratory focusing on biomaterials and stem cells. As an entrepreneur, he co-founded and led Obsidio Inc, a venture backed medical device company that pioneered a biomaterial technology with applications in haemorrhage control and interventional oncology. Obsidio was launched in 2019, received FDA clearance in July 2022, and was acquired by Boston Scientific in August 2022. As an academic leader, he oversaw the National Science Foundation (NSF) funded I-Corps as well as the Technology Innovation and Entrepreneurial Engineering program. Dr. Jabbarzadeh’s credentials include a PhD in chemical engineering from Drexel University, Postdoctoral Fellowship in bioengineering from the California Institute of Technology, and an MBA in finance and entrepreneurship from the University of Southern California, Marshall School of Business.
Interested in Learning More?
Discover our technology, explore opportunities to collaborate, or connect with our team to learn more.